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Abstract In 2014, simultaneous liver kidney transplants
(SLK) accounted for 8.2 % of all liver transplants performed
in the USA. Prior to introduction of the model of end stage
liver disease (MELD) system, SLK accounted for 2.5 % in
2001 and only 1.7 % in 1990. Transplant centers have strug-
gled to balance the moral and ethical aspects of SLK in the
setting of organ scarcity with an algorithm that best qualifies
patients for such treatment options. Few centers have even
ventured into DCD territory for SLK. Advancement in immu-
nosuppression protocols and treatment of HCVand HIV have
impacted SLK over the years. Simulation modeling has
allowed us to analyze the future impact of our decisions that
are made today. All of these advancements have given, and
will continue to give new perspectives to SLK. The purpose of
this review article is to highlight these advances and bring to
light the studies that have made this transplant option
successful.
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Introduction
Since the institution of the model of end stage liver disease
(MELD) system in 2002, experts have been debating the in-
dications for simultaneous liver kidney transplant (SLK), the
correct diagnostic tests needed to make the decision and the
optimal timing for such an operation. The introduction of the
MELD system inadvertently increased the proportion of SLK
and with it spurred a discussion that has been ongoing for the
last 13 years. One of the main reasons for the increase in SLK
in patients with end stage liver disease (ESLD) is the negative
impact of renal non-recovery on liver graft survival, patient
survival, and quality of life [1–3].
In 2014, SLK accounted for 8.2 % of all liver transplants
performed in the USA compared to 4.3 % in 2003. Prior to
introduction of the MELD system, SLK accounted for 2.5 %
in 2001 and only 1.7 % in 1990 [4]. There have been two
consensus conferences about SLK conducted by the American
Society of Transplant Surgery (ASTS), United Network of
Organ Sharing (UNOS), American Society of Transplant
(AST), and American Society of Nephrology (ASN) since
2002. The first report by Eason et al. [5] in 2008 illustrated
the established guidelines for evaluation, listing, and trans-
plantation of patients with end-stage liver disease (ESLD)
and renal failure. The second report, by Nadim et al. in
2012, critically evaluated and published registry data regard-
ing patient and renal outcomes following liver transplantation
alone (LTA) or SLK [6•] (Table 1).
Current Data on Evaluation and Selection Criteria
for SLK in Patients With ESLD
One of the important questions raised is when to consider SLK
versus LTA or kidney after liver transplant (KALT). In patients
with ESLD, pre-transplant renal function has shown to be an
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independent predictor of post-transplant mortality. The pres-
ence of end stage renal disease (ESRD) concomitantly with
ESLD makes the decision to proceed with SLK relatively
pedestrian. Conversely, having normal renal function in the
setting of ESLD makes LTA an obvious choice. The decision
for SLK can be difficult in the setting of hepato-renal syn-
drome (HRS), acute renal failure (ARF), and chronic kidney
disease (CKD) in the setting of ESLD. Currently, transplant
programs often follow center-specific protocols that are mod-
ified based on individual patient characteristics.
In order to standardize the selection criteria for SLK, the
ASTS put forward recommendations in the setting of ARF
and CKD. These recommendations are necessary because
not all patients with ARF on dialysis at the time of liver trans-
plant need a kidney allograft. The duration of dialysis pre-
transplant has shown to play an important role in making that
distinction. The consensus conference in 2006 suggested a
threshold of at least 6 weeks of dialysis before being consid-
ered for SLK. That being said approximately 24 % of patients
may regain renal function having been on dialysis between 8
and 12 weeks. Studies by Ruiz et al. [7], Davis et al. [8],
Northup et al. [9], and Marik et al. [10] demonstrated that a
majority of patients with ARF recover renal function despite
being on dialysis at the time of transplant. Northup et al. dem-
onstrated that SLK should be considered in patients that have
been on dialysis for greater than 90 days [9].
Patient factors such as hypertension, diabetes, age, and eti-
ology of ARF are associated with progression to chronic kid-
ney disease that negatively impacts survival after LTA. It is
however difficult to determine exactly which patients with
borderline renal function will benefit from SLK or LTA
followed by kidney transplant. Angeli Chopra et al. published
data demonstrating that duration of hemodialysis pre-
transplant played a primary role in decision-making in case
of acute renal failure [11]. She also reported the use of renal
biopsy in the setting of CKD to help determine candidates for
SLK based on degree of interstitial fibrosis (30 %),
glomerulosclerosis (40 %), or severe glomerular injury and
Table 1 Evolution of Recommendations and Guidelines for SLK
▪ Nadim et al. [6•]
• Candidates with persistent AKI for≥4 weeks with one of the following:
i. Stage 3 AKI as defined by modified RIFLE, i.e., a threefold increase in serum creatinine (Scr) from baseline, Scr≥4.0
mg/dL with an acute increase of ≥0.5 mg/dL or on renal replacement therapy
ii. Glomerular filtration rate (GFR)≤35 mL/min (MDRD-6 equation) or GFR≤25 mL/min (iothalamate clearance).
•Candidates with CKD, as defined by the National Kidney Foundation for 3 months with one of the following:
i. eGFR≤40 mL/min (MDRD-6 equation) or GFR≤30 mL/min (iothalamate clearance)
ii. Proteinuria≥2 g a day
iii. Kidney biopsy showing >30 % global glomerulosclerosis or >30 % interstitial fibrosis
iv. Metabolic disease
▪ OPTN Kidney Transplantation Committee and the Liver and Intestinal Organ Transplantation Committee (OPTN Policy 3.5.10)
a. CKD requiring dialysis with documentation of the CMS form 2728
b. CKD (GFR≤30 mL/min by MDRD-6 or iothalamate measurement and proteinuria>3 g/day
c. Sustained AKI requiring dialysis for 6 weeks or more (defined as dialysis at least twice per week for 6 consecutive weeks)
d. Sustained AKI (GFR≤25 mL/min for 6 weeks or more by MDRD6 or direct measurement) not requiring dialysis
e. Sustained AKI: Patients may also qualify for SLK listing with a combination of time in categories (c) and (d) above for a
total of 6 weeks (e.g., patients with a GFR<25 mL/min for 3 weeks followed by dialysis for 3 weeks).
f. Metabolic disease
▪ Eason et al. [5]
a. Patients with ESRD with cirrhosis and symptomatic portal hypertension or hepatic vein wedge pressure gradient >/ = 10 mmHg
b. Patients with CKD with GFR≤30 mL/min
c. Patients with AKI/HRS with Scr≥2 mg/dL and dialysis≥8 weeks
d. Patients with evidence of CKD and kidney biopsy demonstrating >30 % glomerulosclerosis or 30 % fibrosis
Other criteria recommended are the presence of comorbidities such as diabetes, hypertension, age>65 years, other preexisting renal
disease along with proteinuria, renal size, and duration of elevated serum creatinine.
▪ Davis et al. [8]
a. Patients with CKD with a measured creatinine clearance (or preferentially an iothalamate clearance) of ≤30 mL/min
b. Patients with AKI and/or HRS on dialysis for ≥6 weeks
c. Patients with prolonged AKI with kidney biopsy showing fixed renal damage
d. SLK not recommended in patients with AKI not requiring dialysis
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degree of arteriosclerosis adapted from papers published by
Gonwa et al. [12]. However, because of concern for bleeding
complications in the setting of coagulopathy, renal biopsies
have not been routinely used. Jouet et al. in 1996 demonstrat-
ed effective and safe use of transjugular kidney biopsy [13].
Other papers more recently have also demonstrated safe utili-
zation of this technique in patients with liver disease to deter-
mine or rule out chronic renal pathology [14]. Our institutional
protocol for SLK is based on adaptations of previously pub-
lished criteria by Eason et al. and Nadim et al. (Fig 1) [5, 6•].
Table 1 lists the evolution of different recommendations and
guidelines for SLK.
SLK in the era of Organ Shortage
Before the MELD era SLK was reserved for patients with
fixed renal disease requiring at least 4 weeks of dialysis. This
strategy maintained a low SLK rate with excellent graft and
patient outcome post-transplant. Introduction of the MELD
score placed higher emphasis on serum creatinine and there-
fore increased the number of SLK. In the MELD era, the
overall 1-year kidney graft survival after SLK is 77.2 % in
comparison with kidney transplant alone (KTA), which is
89.3 %. This decline in renal graft survival could be a result
of transplanting sicker patients in this era. While SLK pro-
vides substantial clinical advantages to many recipients, it
may also divert the kidneys away from patients most in need
for kidney transplant. It is therefore imperative that SLK be
performed in patients that are more likely to have no return in
native renal function.
Recently, Sharma et al. [15•] performed a retrospective
review using SRTR data that analyzed 2112 adult deceased
donor liver transplant (LT) recipients who received acute renal
replacement therapy (RRT) for less than 90 days before LTA.
She concluded that native renal function recovered in majority
of the patients within 6 months post-transplant. The cumula-
tive risk of renal non-recovery was 8.9 % and factors such as
age at LT, longer duration of RRT, re-transplant, and pre-LT
diabetes were significant risk factors of renal non-recovery.
Patients without these risk factors should not be routinely
listed for SLK. Similarly, Brennan et al. [16•] demonstrated
that overall, 87 % of LTA patients with underlying renal dis-
ease recovered renal function within 1 month of transplant and
that SLK in such patients would not have substantially im-
proved patient survival in the short term.
Levitsky et al. demonstrated that after multivariate analysis
(analyzing UNOS criteria and center specific data), only ab-
normal renal imaging <3months pre-SLKwas associatedwith
native renal non-recovery (nGFR≤20 mL/min) post-SLK
(OR=3.85, 95 % CI=1.22–12.50) [17]. A summary of the
predictors of renal non-recovery can be found in Table 2. Oth-
er studies demonstrate maximal gains in survival after SLK in
those patients who have high MELD scores (>30) and those
who have been on dialysis for >90 days [18]. On the other
hand, Locke et al. demonstrated that outcome of kidney grafts
is better for patients who are on long-term dialysis with
MELD scores less than 23 [19]. Kiberd et al. [20] examined
whether greater net patient survival would result from separate
allocation of a liver and kidney to two transplant candidates
versus SLK to a single candidate. He demonstrated that sepa-
rate allocation led to greater total quality adjusted life years
unless the SLK recipient had a very high probability of ESRD
by 1-year post-transplant. Martin et al. retrospectively ana-
lyzed and compared patient and graft survival between pa-
tients that received LTA, SLK, kidney after liver transplant
(KALT), and liver after kidney transplant (LAKT). He found
5 % decreased risk of graft loss with SLK versus LTA (hazard
ratio=0.85, P<0.001). The recipient and graft survival rates
with SLK were higher than the rates with both KALT
(P<0.001 and P<0.001) and LAKT (P=0.003 and
Fig. 1 Algorithm for acute and
chronic kidney disease in patients
with ESLD [5, 6•]
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P<0.001) suggesting justified use of SLK in patients having
ESLD with underlying ARF or CKD [21].
As most centers have independent selection criteria, SLK
does not always result in the best societal outcomes for CKD
patients waiting transplant. Given the wide variation in SLK
rates across regions, it is likely that certain centers overuse or
underuse dual transplantation. Nadim et al. demonstrated this
diversity in treatment regimens by conducting a nation-wide
survey of practice patterns of centers that perform SLK. He
showed that 73 % of centers used dialysis duration whereas
only 30 % of centers used acute kidney injury duration as a
criterion for determining need for SLK. Dialysis duration
>4 weeks was used by 32 % of centers, >6 weeks by 37 %,
and >8 weeks by 32 % of centers. GFR was estimated using
the modified diet in renal disease (MDRD)-4 equation in
roughly half of centers whereas the MDRD-6 equation was
used by only 6 %. In patients with chronic kidney disease,
GFR<40 mL/min was used by 24 % of centers as a criterion
for SLK instead of the recommended threshold of <30 mL/
min [22].
In order to guide future UNOS policies in the USA, Chang
et al. [23•] performed a simulation analysis using the Markov
model to study the impact of proposed SLK policies. This
model tallied outcomes, including numbers of procedures
and life years after LTA or SLK over a 30-year period.
With 1-week pre-transplant dialysis duration, the number
of SLK and LTAs would be 648 and 9065, respectively.
At 12 weeks, there would be 240 SLK and 9426 LTAs.
This change resulted in a decrease of 6483 life years
among SLK recipients and an increase of 4971 life years
among LTA recipients. However, by increasing the dialy-
sis duration to 12 weeks from 1 week, 408 kidney grafts
would be released to the kidney waitlist because of the
decline in SLK; this yields 796 additional life years
gained among ESRD patients. The implementation of
the proposed SLK policy could restore access to kidney
transplants for patients with ESRD at the detriment of
patients with ESLD and renal impairment. A previously
performed simulation study by the same author demon-
strated maximum survival benefit in patients with the
highest MELD score and longest pre-transplant RRT
when compared to patients who receive sequential trans-
plants [24•].
SLK in Pediatric Population
SLK accounts for 1.8 % (274 off 14,733) of all pediatric liver
transplants and 4.4 % of all SLK performed to date (274 off
6149) [25]. The most common indication being primary
hyperoxaluria; congenital hepatic fibrosis; polycystic kidney
disease; and other unknown factors [26]. Calinescu et al. an-
alyzed the largest series to date with 152 pediatric SLK. Pa-
tient survival was 86.8, 82.1, and 78.9 % at 1, 5, and 10 years.
Liver graft survival 81.9, 76.5, and 72.6 %, and kidney graft
survival was 83.4, 76.5 and 66.8 %, respectively. He showed
that patient survival after SLK was equal to isolated liver
transplant but inferior to isolated kidney transplant in the pe-
diatric population. In his analysis, primary hyperoxaluria (PH)
was associated with reduced patient, liver graft, and kidney
graft survival (p=0.01) [27]. Non-PH patients did better over-
all. His analysis corroborated the findings from previously
published smaller studies.
Ongoing Clinical Research and Development
Minimization of Calcineurin Inhibitors (CNIs) in SLK
Newer immunosuppressive strategies that minimize reliance
on CNIs may decrease the need for SLK in patients with low
GFR by preserving renal function post-orthotopic liver trans-
plant. One such protocol employed by our institution is rabbit
antithymocyte globulin (RATG) induction in a steroid-free
protocol with delayed introduction and minimization of CNIs
[28•, 29, 30]. However, more work is needed in this field.
SLK in HIV-Positive Recipients
In the era of highly active antiretroviral (HAART) therapy,
human immunodeficiency virus (HIV) has become a chronic
disease. Multiple studies have demonstrated effective and safe
single organ transplants in the setting of HIV with or without
co-infections such as HCVor hepatitis B (HBV) [31, 32] with
similar graft and patient survival. A group from Italy reported
two cases of SLK in HIV patients co-infected with HCV in
2011 with preserved graft function in both patients, (1 and
3 years after transplant) [33]. Larger studies in the future will
be needed to determine the efficacy and reliability of SLK in
this population of patients.
SLK Using Organs from Donation after Cardiac Death
(DCD) Donors
With increasing number of patients waiting for transplant,
centers have explored the utility of DCD donors in cases of
SLK. Two recent retrospective analyses of UNOS data com-
pared outcomes of SLK using DCD and DBD donors. Both
studies have demonstrated inferior graft survival (both liver
Table 2 Summary of predictors of renal non-recovery post LT in
patients with underlying renal disease
1. Duration of pre-transplant dialysis (>90 days)
2. Age at liver transplant
3. Type II diabetes
4. Re-transplant
5. Abnormal renal imaging pre-transplant
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and kidney) and patient survival at 3 and 5 years post trans-
plant. That being said patient survival is about 56.7 to 57.5 %
at 5 years despite overall inferior graft survival [34, 35]. Fu-
ture prospective studies will be needed to improve criteria for
DCD-SLK. For now, DCD-SLK is not recommended.
SLK in the era of Direct Acting Anti-Viral Therapy
and Interferon-Free Regimens in HCV Positive Patients
Outcomes of graft survival, patient survival, and recurrence of
hepatitis C after SLK in HCV positive patients are comparable
to LTA [36]. However, re-transplantation in the setting of
HCV recurrence has been considered a contraindication. Until
recently interferon-based treatment was the only available
treatment for recurrent hepatitis C with a 50 % response rate.
Newer direct acting anti-viral therapies and interferon-free
regimens have shown to have less drug–drug interaction with
immunosuppression and have demonstrated improved
sustained viral response in the setting of liver transplantation
[36]. The use of such treatment modalities is fairly recent with
no long-term results. Application of newer HCV treatment in
SLK is something to be expected in the future.
Future Direction in SLK
There is an urgent need to standardize allocation policies
employing the most recent available data to best balance util-
ity and equity. Once such proposal being consider by the 2015
SLK, UNOS work group involves re-evaluating the medical
eligibility criteria for SLK and providing prioritization of kid-
ney transplantation to patients who develop significant renal
dysfunction (eGFR<20ml/min) or ESRDwithin 2–12months
of receiving a liver allograft. The new eligibility criteria for
SLK will take into consideration the nature of kidney disease
(acute, chronic, or metabolic in origin) and duration of dialysis
in addition to GFR and/ or creatinine clearance. Evidence of
patients meeting these criteria will be necessary in order for
them to quality for SLK. These strategies will not only prevent
unnecessary SLK but will also decrease the morbidity and
mortality associated with renal dysfunction post-OLT by pro-
viding a safety-net to patients with declining renal function.
Conclusion
It is clear that patients with ESLD and need for dialysis do
poorly and that SLK can improve liver graft survival and, in
selected patients, overall survival. Also, everyone is fully
aware of the shortage in organ availability and the need to
allocate organs to best balance equity and utility.
The increasing number of SLK over the past decade has
allowed transplant centers to accrue valuable data for analysis
and meaningful use. For now, most protocols for patient
selection are center-specific, although influenced by published
reviews. More work is needed to provide universally accept-
able guidelines for SLK. Newer HCV treatment regimens will
also have an impact on graft and patient survival and may
change the paradigm for re-transplantation in these patients.
SLK in HIV-positive patients is in its infancy at this time with
limited data available for developing stringent guidelines. Im-
munosuppressive regimens with decreased reliance on CNIs
may preserve renal function in patients with intermediate GFR
and decrease the need for SLK. DCD-SLK may prove to be
another option to decrease wait list time and expand our donor
pool. However, more work is needed to help improve out-
comes in this field. Stewardship for organs and patients in
the setting of multi-organ transplant is challenging. Standard-
ized allocation guidelines and analysis of center-specific out-
comes will allow for a greater balance of utility and equity.
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